Illumina, Inc. ILMN
We take great care to ensure that the data presented and summarized in this overview for ILLUMINA, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ILMN
View all-
Black Rock Inc. New York, NY18.1MShares$1.6 Billion0.04% of portfolio
-
Capital World Investors Los Angeles, CA18MShares$1.6 Billion0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.8MShares$1.4 Billion0.04% of portfolio
-
State Street Corp Boston, MA5.79MShares$514 Million0.03% of portfolio
-
Loomis Sayles & CO L P4.21MShares$374 Million0.71% of portfolio
-
Wcm Investment Management, LLC Laguna Beach, CA4.13MShares$366 Million1.52% of portfolio
-
Baillie Gifford & CO3.02MShares$268 Million0.32% of portfolio
-
Geode Capital Management, LLC Boston, MA2.73MShares$243 Million0.03% of portfolio
-
Primecap Management CO Pasadena, CA2.46MShares$218 Million0.26% of portfolio
-
Guardcap Asset Management LTD London, X02.4MShares$213 Million5.18% of portfolio
Latest Institutional Activity in ILMN
Top Purchases
Top Sells
About ILMN
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.
Insider Transactions at ILMN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 18
2025
|
Patricia Leckman SVP, Chief People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,756
-12.57%
|
$175,600
$100.0 P/Share
|
Feb 18
2025
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
SELL
Sale (or disposition) back to the issuer
|
Direct |
460
-6.81%
|
$46,000
$100.0 P/Share
|
Feb 15
2025
|
Scott D Ericksen VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
272
-2.85%
|
$27,472
$101.09 P/Share
|
Feb 15
2025
|
Scott M Davies Interim General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
407
-3.3%
|
$41,107
$101.09 P/Share
|
Feb 15
2025
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
529
-2.03%
|
$53,429
$101.09 P/Share
|
Feb 15
2025
|
Patricia Leckman SVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
644
-4.41%
|
$65,044
$101.09 P/Share
|
Feb 15
2025
|
Jacob Thaysen Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,064
-4.65%
|
$208,464
$101.09 P/Share
|
Feb 15
2025
|
Carissa Rollins SVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
513
-4.42%
|
$51,813
$101.09 P/Share
|
Feb 15
2025
|
Kevin Carl Pegels Chief of Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
565
-3.45%
|
$57,065
$101.09 P/Share
|
Jan 05
2025
|
Patricia Leckman SVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-6.81%
|
$147,384
$138.65 P/Share
|
Jan 05
2025
|
Scott M Davies Interim General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-7.97%
|
$147,384
$138.65 P/Share
|
Jan 05
2025
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-3.94%
|
$147,384
$138.65 P/Share
|
Jan 05
2025
|
Scott D Ericksen VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,068
-10.08%
|
$147,384
$138.65 P/Share
|
Dec 31
2024
|
Scott B. Ullem Director |
BUY
Grant, award, or other acquisition
|
Direct |
158
+3.13%
|
$22,436
$142.06 P/Share
|
Dec 06
2024
|
Christensen Jakob Wedel SVP, Strategy/Corp Development |
SELL
Payment of exercise price or tax liability
|
Direct |
396
-5.53%
|
$55,440
$140.02 P/Share
|
Nov 05
2024
|
Steven Barnard SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
476
-1.73%
|
$73,304
$154.96 P/Share
|
Nov 05
2024
|
Carissa Rollins SVP, Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
412
-3.43%
|
$63,448
$154.96 P/Share
|
Nov 05
2024
|
Scott M Davies Interim General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
474
-3.42%
|
$72,996
$154.96 P/Share
|
Nov 05
2024
|
Scott D Ericksen VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
257
-2.37%
|
$39,578
$154.96 P/Share
|
Nov 05
2024
|
Kevin Carl Pegels Chief of Global Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
699
-4.1%
|
$107,646
$154.96 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 151K shares |
---|
Payment of exercise price or tax liability | 14.9K shares |
---|---|
Sale (or disposition) back to the issuer | 4.19K shares |